AndhraNews.net
Home » Business News » 2011 » December » December 5, 2011

Frost & Sullivan Commends Biodesix for Raising the Bar in Personalized Medicine Diagnostics With the VeriStrat(R) Test


December 5, 2011 - Mountain View, CA

Based on its recent analysis of the cancer diagnostics market, Frost & Sullivan recognizes Biodesix with the 2011 North America Frost & Sullivan Award for Product Differentiation Excellence. Biodesix's significant investment in validation, clinical research and basic R&D has made it a leading diagnostic service provider in an industry that often lacks clinically validated biomarkers. Its VeriStrat Blood test is a new approach to non-small cell Lung Cancer (NSCLC) diagnostics and is a first-of-its-kind, highly reproducible matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) proteomic assay.

Biodesix uses the MALDI-MS platform to generate spectra that contains eight proteomic peaks, which comprise the VeriStrat classifier. This is used to differentiate patients that may or may not benefit from epidermal growth factor receptor (EGFR) inhibitors as a second-line treatment.

"In developing VeriStrat, Biodesix has addressed the issue of data reproducibility in MALDI-MS, which had previously impeded clinical adoption, despite the benefits in Protein profiling," says Frost & Sullivan Research Analyst Winny Tan. "With key advances such as improved signal-to-noise-ratio, differential measurement and algorithm optimization in the data acquisition processes, Biodesix has achieved high reproducibility."

Biodesix has a differentiated approach to Lung Cancer diagnostic testing. Rather than measuring mutations that are potentially oncogene-activating, VeriStrat captures current information about the patient that may have changed since he or she was first diagnosed or when a tissue biopsy was, most likely, performed.

Recently, Biodesix streamlined all aspects of sample collection and workflow. Its lab's rapid turnaround time of 72 hours is a significant improvement. The substantial adoption of the VeriStrat test reported by Biodesix has warranted a sales force expansion from a pilot operation to full-scale project in just four months.

Biodesix developed VeriStrat for NSCLC in response to a need to identify the patients who were likely to benefit from erlotinib therapy in the second-line setting. Available genetic testing was typically done only at diagnosis, before the first-line treatment, and there were no defined markers in the second-line setting.

"Biodesix is finding relevant signatures in renal, colorectal, head and neck and breast sample sets," notes Tan. "Biodesix supplements these useful results with a market analysis to ensure that its tests fulfill unmet clinical and market needs."

The funding of large prospective phase III studies by Biodesix demonstrates a strong commitment toward improving patient outcomes by clinical validation and positions the company as a best-in-practice diagnostic test developer.

Each year, Frost & Sullivan presents this award to the company that has demonstrated superior features and functionality as well as quality and complexity. The company has also exhibited high levels of customization, excellent product mix and met the requirements of its target market.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About Biodesix

Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. The Company's goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes. The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

MarketWire

Comment on this story

Share